stockrow
Friday 6 November 2026
Export INCR’s income statement to Excel — free account
InterCure Ltd.
INCR Healthcare Drug Manufacturers Specialty & Generic
InterCure Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $78.5 million, up 18.4% from fiscal 2024.
3.36
0.06
+1.82%
Follow INCR
Alert me
| Jun '25 | Jun '24 | Jun '23 | Mar '23 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 16.05 | 2.04 |
+8 more quarters Free account |
P/S ratio |
— | — | 3.22 | 0.14 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (26.04) | (1.17) | |
P/B ratio |
— | — | 2.68 | 0.12 | |
Price to Tangible BV |
— | — | 5.81 | 0.26 | |
EV/Sales |
— | — | 3.20 | 0.31 | |
EV/EBITDA |
— | — | 35.36 | 2.71 | |
EV/Operating CF |
— | — | (1,502.70) | (149.70) | |
EV/FCF |
— | — | (92.12) | (9.18) | |
Quick Ratio |
1.09 | 1.15 | 1.21 | 1.24 | |
Current Ratio |
1.85 | 1.78 | 1.90 | 1.83 | |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 8.07 | |
Debt/Assets |
15.51% | 9.32% | 12.52% | 22.15% | |
Debt/Equity |
0.27 | 0.15 | 0.20 | 0.37 | |
Asset Turnover |
0.00 | 0.00 | 0.51 | 0.51 | |
Operating CF/Net income |
0.00 | — | 0.00 | (245.44) | |
Capex/Depreciation |
(0.38) | — | — | (0.22) | |
Interest Coverage |
— | — | 0.00 | 1.04 | |
Research and Development Expense of Revenue |
— | — | 0.10% | 0.14% | |
Selling, General and Administrative Expense of Revenue |
— | — | 25.21% | 23.73% | |
Intangible Assets out of Total Assets |
0.30 | 0.30 | 0.34 | 0.32 | |
Share Based Compensation of Revenue |
0.00% | — | 0.00% | 1.28% | |
Graham Net Nets |
— | — | 0.06 | 1.19 | |
Graham Number |
— | — | 6.15 | 19.73 | |
Earnings Yield |
— | — | 6.23% | 49.02% | |
Free Cash Flow Yield |
— | — | (1.08%) | (23.90%) | |
Revenue per Share |
— | — | 0.60 | 3.65 | |
Operating CF per Share |
0.00 | — | 0.00 | (1.74) | |
Capex per Share |
0.00 | — | 0.00 | (0.02) | |
Free Cash Flow per Share |
0.00 | — | 0.00 | (1.76) | |
Cash per Share |
0.00 | 0.00 | 0.00 | 3.98 | |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 17.30 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.00 | 0.00 | 0.00 | 17.30 | |
Free Cash Flow |
2.50 | — | — | (15.07) | |
Working Capital |
48.10 | 43.42 | 51.17 | 54.53 | |
Capital Expenditures |
(0.91) | — | — | (0.19) | |
Net Current Asset Value |
15.23 | 24.68 | 22.01 | 20.76 | |
EV/EBIT |
— | — | 36.60 | 3.65 | |
Capex to Sales |
0.00 | — | 0.00 | 0.01 | |
Price to Operating Income |
— | — | 36.87 | 1.66 | |
| Other line items | |||||
Average Receivables |
43.29 | 46.37 | 29.32 | 31.71 | |
Average Payables |
31.48 | 25.54 | 26.86 | 27.07 | |
Average Inventory |
40.30 | 37.33 | 34.42 | 33.94 | |
Average Assets |
247.84 | 228.13 | 233.86 | 240.50 | |
Average Common Equity |
138.13 | 137.55 | 147.33 | 149.95 |
Columns are period end dates · fundamentals updated 26 Oct 2026